Although the concentration of GM-CSF showed a gradually decreasing tendency in the serum of tumor-bearing mice with tumor progression in the melanoma model [53], treatment of monocytes with GM-CSF was required for the licensing of monocytes to be suppressive cells [54]. This evidence concerns the gene CSF2 and neoplasm.